Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Scohia Pharma, Inc.

Yasufumi Miyamoto

Tomohiro Okawa

Akito Shibuya

Yasuhiro Hirata

Seiji Miwatashi

Yuko Hitomi

Junya Shirai

Nobuyuki Takakura

Zenyu Shiokawa

Yuta Tanaka

Nobuyuki Matsunaga

Takashi Nakahata

Koji Watanabe

Hideki Furukawa

Jumpei Aida

Naoyoshi Noguchi

Takeshi Yamasaki

Hideo Suzuki

Tsuneo Yasuma

Malcolm Maccoss

Takuto Kojima

Shinichi Imamura

Xiaolun Wang

Tsuyoshi Maekawa

Keiko Kakegawa

Nicholas Scorah

Yasutomi Asano

Minoru Yoshida

John S Tyhonas

Shizuo Kasai

Phong H Vu

Mark Sabat

Terufumi Takagi

Tzu-Tshin Wong

Toshitake Kobayashi

Shuji Kitamura

Joanne Miura

Rei Okamoto

Yoichi Nishikawa

Osamu Kurasawa

Haixia Wang

Yoshito Terao

Takafumi Yukawa

Lily Kwok

Mallareddy Komandla

Kazuko Yonemori

Yayoi Nakayama

Naoki Iwamura

Takeshi Yoshikawa

Ryosuke Arai

Hiroki Takahagi

Bunnai Saito

Paul Tanis

Osamu Sano

Satoshi Sasaki

Norihito Tokunaga

Kazuaki Takami

Shigemitsu Matsumoto

Yayoi Yoshitomi

Akira Kawada

Arai Ryosuke

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description,or a pharmaceutically acceptable salt thereof.

Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

Aromatic compound

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Aminopyrimidine compound

Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy. 

Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

Heterocyclic compound

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Aromatic compounds with GPR40 agonistic activity

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

The present invention provides an agent for the prophylaxis or treatment of diabetes, obesity and the like, a glucokinase activator, containing a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.

Fused ring compound and use thereof

The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like. A glucokinase activator containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity

Growing community of inventors

Kanagawa, Japan

Yasufumi Miyamoto